ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets
- 1 October 2006
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 112 (1) , 139-149
- https://doi.org/10.1016/j.pharmthera.2006.04.002
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemiaCytokine, 2005
- Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusionKidney International, 2005
- Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injuryBritish Journal of Pharmacology, 2004
- Key role of proline‐rich tyrosine kinase 2 in interleukin‐8 (CXCL8/IL‐8)‐mediated human neutrophil chemotaxisImmunology, 2004
- Inflammation and cancerNature, 2002
- A RANDOMIZED MULTICENTER TRIAL COMPARING LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 MONOCLONAL ANTIBODY WITH RABBIT ANTITHYMOCYTE GLOBULIN AS INDUCTION TREATMENT IN FIRST KIDNEY TRANSPLANTATIONSTransplantation, 1996
- Delayed Graft Function in Renal Transplantation: Etiology, Management and Long-term SignificanceJournal of Urology, 1996
- Antibodies against the N-terminus of IL-8 Receptor A Inhibit Neutrophil ChemotaxisBiochemical and Biophysical Research Communications, 1996
- Both interleukin‐8 receptors independently mediate chemotaxisFEBS Letters, 1994
- Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8Biochemical and Biophysical Research Communications, 1990